Kenny S. Frazier
Keine laufenden Positionen mehr
Profil
Kenny S.
Frazier held the position of Senior Director-Clinical Operations at Lexicon Pharmaceuticals, Inc. and the position of VP-Clinical Development & Regulatory Affairs at Opexa Therapeutics, Inc. He obtained an undergraduate degree from Texas Tech University.
Ehemalige bekannte Positionen von Kenny S. Frazier
| Unternehmen | Position | Ende |
|---|---|---|
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
| LEXICON PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 13.09.2012 |
Ausbildung von Kenny S. Frazier
| Texas Tech University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
